Cargando…

A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation

Alzheimer's disease (AD), the most common form of dementia, has emerged as a major global public health challenge. However, the complexity of AD in its biological, genetic, and clinical aspects has hindered the development of effective therapeutic agents. Research plans that integrate new drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Hyun, Noh, Min Young, Kim, Hee-Jin, Oh, Ki-Wook, Park, Jinseok, Lee, Sanggon, Moon, Yeonsil, Kim, Young-Eun, Bae, Jae-sung, Jin, Hee Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Dementia Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609533/
https://www.ncbi.nlm.nih.gov/pubmed/31297134
http://dx.doi.org/10.12779/dnd.2019.18.2.33
_version_ 1783432328139243520
author Kim, Seung Hyun
Noh, Min Young
Kim, Hee-Jin
Oh, Ki-Wook
Park, Jinseok
Lee, Sanggon
Moon, Yeonsil
Kim, Young-Eun
Bae, Jae-sung
Jin, Hee Kyung
author_facet Kim, Seung Hyun
Noh, Min Young
Kim, Hee-Jin
Oh, Ki-Wook
Park, Jinseok
Lee, Sanggon
Moon, Yeonsil
Kim, Young-Eun
Bae, Jae-sung
Jin, Hee Kyung
author_sort Kim, Seung Hyun
collection PubMed
description Alzheimer's disease (AD), the most common form of dementia, has emerged as a major global public health challenge. However, the complexity of AD in its biological, genetic, and clinical aspects has hindered the development of effective therapeutic agents. Research plans that integrate new drug discoveries are urgently needed, including those based on novel and reliable biomarkers that reflect not only clinical phenotype, but also genetic and neuroimaging information. Therapeutic strategies such as stratification (i.e., subgrouping of patients having similar clinical characteristics or genetic background) and personalized medicine could be set as new directions for developing effective drugs for AD. In this review, we describe a therapeutic strategy that is based on immune-inflammation modulation for a subgroup of AD and related dementias, arguing that the use of stratification and personalized medicine is a promising way to achieve targeted medicine. The Korean AD Research Platform Initiative based on Immune-Inflammatory biomarkers (K-ARPI) has recently launched a strategy to develop novel biomarkers to identify a subpopulation of patients with AD and to develop new drug candidates for delaying the progression of AD by modulating toxic immune inflammatory response. Sphingosine kinase 1 (SphK1) and its metabolites, triggering receptor expressed on myeloid cells-2 (TREM2) related signals, and actin motility related proteins including Nck-associated protein 1 (Nap1) were selected as promising targets to modulate neuroinflammation. Their roles in stratification and personalized medicine will be discussed.
format Online
Article
Text
id pubmed-6609533
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Dementia Association
record_format MEDLINE/PubMed
spelling pubmed-66095332019-07-11 A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation Kim, Seung Hyun Noh, Min Young Kim, Hee-Jin Oh, Ki-Wook Park, Jinseok Lee, Sanggon Moon, Yeonsil Kim, Young-Eun Bae, Jae-sung Jin, Hee Kyung Dement Neurocogn Disord Review Article Alzheimer's disease (AD), the most common form of dementia, has emerged as a major global public health challenge. However, the complexity of AD in its biological, genetic, and clinical aspects has hindered the development of effective therapeutic agents. Research plans that integrate new drug discoveries are urgently needed, including those based on novel and reliable biomarkers that reflect not only clinical phenotype, but also genetic and neuroimaging information. Therapeutic strategies such as stratification (i.e., subgrouping of patients having similar clinical characteristics or genetic background) and personalized medicine could be set as new directions for developing effective drugs for AD. In this review, we describe a therapeutic strategy that is based on immune-inflammation modulation for a subgroup of AD and related dementias, arguing that the use of stratification and personalized medicine is a promising way to achieve targeted medicine. The Korean AD Research Platform Initiative based on Immune-Inflammatory biomarkers (K-ARPI) has recently launched a strategy to develop novel biomarkers to identify a subpopulation of patients with AD and to develop new drug candidates for delaying the progression of AD by modulating toxic immune inflammatory response. Sphingosine kinase 1 (SphK1) and its metabolites, triggering receptor expressed on myeloid cells-2 (TREM2) related signals, and actin motility related proteins including Nck-associated protein 1 (Nap1) were selected as promising targets to modulate neuroinflammation. Their roles in stratification and personalized medicine will be discussed. Korean Dementia Association 2019-06 2019-06-24 /pmc/articles/PMC6609533/ /pubmed/31297134 http://dx.doi.org/10.12779/dnd.2019.18.2.33 Text en © 2019 Korean Dementia Association https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kim, Seung Hyun
Noh, Min Young
Kim, Hee-Jin
Oh, Ki-Wook
Park, Jinseok
Lee, Sanggon
Moon, Yeonsil
Kim, Young-Eun
Bae, Jae-sung
Jin, Hee Kyung
A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
title A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
title_full A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
title_fullStr A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
title_full_unstemmed A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
title_short A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
title_sort therapeutic strategy for alzheimer's disease focused on immune-inflammatory modulation
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609533/
https://www.ncbi.nlm.nih.gov/pubmed/31297134
http://dx.doi.org/10.12779/dnd.2019.18.2.33
work_keys_str_mv AT kimseunghyun atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT nohminyoung atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT kimheejin atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT ohkiwook atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT parkjinseok atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT leesanggon atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT moonyeonsil atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT kimyoungeun atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT baejaesung atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT jinheekyung atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT atherapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT kimseunghyun therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT nohminyoung therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT kimheejin therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT ohkiwook therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT parkjinseok therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT leesanggon therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT moonyeonsil therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT kimyoungeun therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT baejaesung therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT jinheekyung therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation
AT therapeuticstrategyforalzheimersdiseasefocusedonimmuneinflammatorymodulation